Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.

Robert J MotzerBernard EscudierDavid F McDermottOsvaldo Arén FronteraBohuslav MelicharThomas PowlesFrede DonskovElizabeth R PlimackPhilippe BarthélémyHans J HammersSaby GeorgeViktor GrünwaldCamillo PortaVictoria NeimanAlain RavaudToni K ChoueiriBrian I RiniPamela SalmanChristian K KollmannsbergerScott S TykodiMarc-Oliver GrimmHoward GurneyRaya Leibowitz-AmitPoul F GeertsenAsim AminYoshihiko TomitaM Brent McHenryShruti Shally SaggiNizar M Tannir

Published in: Journal for immunotherapy of cancer (2021)

NCT02231749.

Keyphrases

renal cell carcinoma
clinical trial
phase ii
open label
study protocol
double blind
phase iii
randomized controlled trial
placebo controlled
clinical evaluation